I-MAB (IMAB) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
I-Mab, a U.S.-based biotech firm, reported promising financial and clinical advancements in its third-quarter 2024 results. The company is set to initiate a Phase 2 study for uliledlimab in lung cancer, with strong early data boosting confidence in its cancer treatment pipeline. With a cash runway extending into 2027 and strategic deals like the Sanofi partnership, I-Mab is poised for significant growth in the coming years.
For further insights into IMAB stock, check out TipRanks’ Stock Analysis page.
